Albeit the phenomenon is currently widespread, the role of licensing in the financing of innovation has been under-investigated by scholars so far. Anecdotal evidence, instead, suggests that in some circumstances licensors is required to further develop the licensed technology which the licensee may finance by paying an upfront fee. Thus, the need for extra finances may affect the decision of the licensor to negotiate and thus actually agree on a specific form of payment. The aim of our paper is to investigate whether financial constrained licensors are more likely to choose an upfront fee-based license and more inclined to credit a portion of the initial fee against future royalties to meet their short-term financing needs. We investigate this issue by combining the Recombinant Capital’s Biotech Alliance (Recap) with Compustat and the USPTO patent database.

Financial constraints in Markets for technology: Licensing as a source of finance / Leone, MARIA ISABELLA; Moreira, Solon; Oriani, Raffaele. - In: ACADEMY OF MANAGEMENT ANNUAL MEETING PROCEEDINGS. - ISSN 2151-6561. - 2015:(2015), pp. 1-1. [10.5465/AMBPP.2015.15091abstract]

Financial constraints in Markets for technology: Licensing as a source of finance

LEONE, MARIA ISABELLA;ORIANI, RAFFAELE
2015

Abstract

Albeit the phenomenon is currently widespread, the role of licensing in the financing of innovation has been under-investigated by scholars so far. Anecdotal evidence, instead, suggests that in some circumstances licensors is required to further develop the licensed technology which the licensee may finance by paying an upfront fee. Thus, the need for extra finances may affect the decision of the licensor to negotiate and thus actually agree on a specific form of payment. The aim of our paper is to investigate whether financial constrained licensors are more likely to choose an upfront fee-based license and more inclined to credit a portion of the initial fee against future royalties to meet their short-term financing needs. We investigate this issue by combining the Recombinant Capital’s Biotech Alliance (Recap) with Compustat and the USPTO patent database.
File in questo prodotto:
File Dimensione Formato  
Leone_etal2015AOMProc_completo.pdf

Solo gestori archivio

Descrizione: "Articolo principale"
Tipologia: Documento in Post-print
Licenza: DRM non definito
Dimensione 851.03 kB
Formato Adobe PDF
851.03 kB Adobe PDF   Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11385/169738
Citazioni
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact